AstraZeneca plc (GB:AZN) has released an update.
AstraZeneca, in collaboration with Daiichi Sankyo, announced that their drug Enhertu significantly improved progression-free survival in patients with certain types of metastatic breast cancer, possibly becoming a new standard of care. The DESTINY-Breast06 Phase III trial showed that Enhertu was more effective than standard chemotherapy in patients who had previously undergone endocrine therapy. Although overall survival data are still maturing, there is an early indication of potential improvement over chemotherapy.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
